“During the past year we remained agile and responsive to capture opportunities in a business landscape that has continued to evolve with the COVID-19 pandemic. We have remained focus on our long-term success by progressing with our growth investment strategy”
“As a Board, our role is to set the company strategy while ensuring we remain resilient to challenges and ready to capture opportunities. Within this framework we have built a strong foundation, enabling the company to pursue its role as a dedicated partner to the healthcare industry.”
Employees (Full-time equivalent)
CORE EBITDA in CHF
Nationalities
CORE EBITDA margin in %
ROIC in %
Trademark filings
Global development and manufacturing sites
Sales in CHF
Brands
Active patent families
Sales growth in %
Years of history
Small and large molecules
“In 2021, we made landmark CAPEX commitments to accelerate organic growth across all our businesses. Looking ahead, alongside driving sales growth, we will renew our focus on productivity in operations and overheads, while maintaining our focused and disciplined capital allocation framework. With that, we are confident to deliver on our Mid-Term Guidance.”
“In 2021, Lonza’s Global COVID-19 Taskforce continued to manage the evolution of the pandemic. Building on the experience gained in 2020, we captured opportunities to replicate best practices and share lessons learned. We followed an agile global approach by pursuing local strategies to deliver the best response for each unique situation.”
“Even during the most challenging times of the COVID-19 pandemic, we have continued to focus on talent attraction, development and retention as critical elements for Lonza’s long-term success. The HR team has worked diligently to recruit new talent in line with Lonza’s ambitious growth plans, while working to retain engaged and established colleagues.”
“During 2021, we successfully implemented our new organizational structure with a clear focus on driving value across divisions, while leveraging synergies and establishing best practices and global standards. Our top priority for 2022 is to improve the delivery of our large portfolio of growth projects and to secure supply continuity.”
“With strong demand for COVID-19 therapeutics, the development of increasingly complex molecules and higher manufacturing demand for new and existing medicines, we made significant investments in people, assets and capabilities within our Biologics business in 2021. We brought new capacities online and announced growth initiatives to further develop our integrated offering.”
“The Small Molecules business saw a significant number of new programs signed and the successful ramp-up of large assets in 2021. As we look ahead, we will continue to adapt to the needs of our portfolio of customers with enhanced ways of working and increased capacity to provide security of supply across all stages of the product lifecycle.”
“To meet our customers’ needs in 2021, we have continued to invest to grow our network and capabilities, strengthen execution and differentiate through innovation. Looking ahead, we will work to further establish our position as a partner of choice for the late-stage clinical and commercial manufacturing of cell and gene therapies.”
“As we look back on another challenging year, I am proud of how CHI has established itself and flourished as a new division. In response to the increasing global demand for capsules, we have delivered against our ambitious expansion plans and as of the end of 2021, we have the capacity to produce around 250 billion capsules annually across the world.”
